Feline Leukemia Virus and Feline Lymphosarcoma by Rasmussen, Glenna
Volume 44 | Issue 1 Article 2
1982
Feline Leukemia Virus and Feline Lymphosarcoma
Glenna Rasmussen
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/iowastate_veterinarian
Part of the Oncology Commons, Small or Companion Animal Medicine Commons, and the
Veterinary Infectious Diseases Commons
This Article is brought to you for free and open access by the Journals at Iowa State University Digital Repository. It has been accepted for inclusion in
Iowa State University Veterinarian by an authorized editor of Iowa State University Digital Repository. For more information, please contact
digirep@iastate.edu.
Recommended Citation
Rasmussen, Glenna (1982) "Feline Leukemia Virus and Feline Lymphosarcoma," Iowa State University Veterinarian: Vol. 44 : Iss. 1 ,
Article 2.
Available at: https://lib.dr.iastate.edu/iowastate_veterinarian/vol44/iss1/2
Feline Leukemia Virus and
Feline Lymphosarcoma
by Glenna Rasmussen, DVM*
SUMMARY
Lymphosarcoma, caused by the feline leu-
kemia virus, is the most common neoplasm of
the feline species. The condition occurs in
cats of all ages and usually runs a very brief
but fatal course. Transmission is both horiz-
0ntal and vertical with the virus being shed in
saliva, urine, feces, and milk. Most frequently
observed symptoms include weight loss, de-
pression, anorexia, and fever. The possibility
of lymphosarcoma should be considered in
any animal having an illness of several weeks
duration, which is characterized by the above
symptoms and having an associated
respiratory condition with signs of sneezing,
coughing, and dyspnea.
Fluorescent antibody, ELISA, and
FOCMA antibody test are available to detect
the virus of virus-induced antibody in blood
of affected cats. No feline leukemia virus vac-
cines are currently available; and though
chemotherapeutic treatment is being ex-
plored, lymphosarcoma should still be con-
sidered an incurable disease at the present
time.
INTR.ODUCTION
The feline leukema virus (FeLV) is a single
stranded RNA virus classified as an oncorna
virus. Its infection in cats is widespread and
related to the density of the cat population
and to host and environmental factors that in-
fluence the severity. Epizootiologic studies in-
dicate that 25-60% of free roaming cats in
urban populations are infected with the virus,
with only 2-6% remaining chronically in-
fected. In rural cat populations and closely
confined single cat households, the infection
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chronically infected. 1
Feline leukemia virus is contagious from
one cat to another and though it appears to
be most easily spread to young cats, all are
susceptible. The virus is shed in saliva urine
and feces of infected cats with infec;ion oc ~
curring when a susceptible cat contacts these
secretions. Transmission can be through oral
and parenteral exposure and can occur when
animals groom or bite each other or share lit-
ter and food containers. Although queens in-
fected with feline leukemia virus usually have
reproductive problems, it has been shown to
be passed in utero to their offspring. Blood
sucking insects may theoretically also spread
the virus. Aerosol transmission is not an im-
portant route of exposure in nature, and
because the virus does not live long outside
the body, the environment is not an impor-
tant reservoir source. 1,2,3,10
Following continuous exposure, virus or
antibody to virus is not detectable until four
weeks. By twenty weeks, 80% of the cats have
been infected. A small percentage, especially
if they are older, may not show evidence of in-
fection until 52 weeks.
The pathogenesis of FeLV infection can be
divided into three stages: primary disease (ap-
parent or inapparent); death, recovery, or
apparent recovery; and recurrent or terminal
illness. Often the primary disease is totally in-
apparent, in which case the virus is elimin-
ated and the cat becomes free of infection.
These cats may never be detectably viremic or
may be viremic for several weeks. Cats that
are ill at this time may show fever, malaise,
anorexia, lymphadenopathy, leukemia, and
thrombocytopenia. Clinical signs persist for
2-16 weeks, with some cats dying. Most cats
that are ill during the prim.ary stage appear to
recover but will remain chronically infected.
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These cats that are chronically viremic may
eventually (within weeks, months, or years)
develop a wide variety of seemingly unrelated
diseases or suffer from recurrence of the
primary myelosuppression. With symp-
tomatic care and prevention of undue stress,
the mortality rate in chronically viremic cats
may be kept to 20% per year.
Studies have shown that the more severe the
primary illness, the more likely it is that the
cat will become chronically viremic. In
nature, most infected cats develop inapparent
or mild primary illness and recover. In cat-
teries and multiple cat households, the
primary illness is likely to be severe and the
proportion of cats developing a chronic infec-
tion higher.
The FeLV causes lymphosarcoma, lympho-
cytic leukemia, myeloproliferative diseases,
and is also implicated directly in other infec-
tious diseases. Feline lymphosarcoma is the
principal tumor caused by FeLV and consists
of solid masses of proliferating lymphocytes.
One study reports the incidence of feline lym-
phosarcoma is 416 per 100,000 cats but other
studies suggest that it may be double that
figure. 1.2
Age incidence is inconsistent, however a
survey of 26 cats at the University of Georgia
over a six year period showed the following;
50% of those infected were 1-3 years; 36%
were 4-8 years; and 14% were greater than 9
years. Fifty percent were male and fifty per-
cent female, though other studies have shown
males to have a three times greater risk.
Siamese cats are reported to have a higher in-
cidence than other breeds. 5
Lymphosarcoma can affect any organ of
the body with clinical signs dependent on the
area of involvement. There are four main
clinical manifestations of lymphosarcoma: 1)
mediastinal; 2) alimentary; 3) multicentric;
and 4) leukemic. 1.2.3.4.5
Mediastinal lymphosarcoma primarily in-
volves the thymus, sternal and anterior
mediastinal lymph nodes, and often causes
pleural effusion. More advanced lesions in-
volve perihylar lymph nodes and lung paren-
chyma. The thoracic mass may become en-
larged, compress the trachea and esophagus,
and result in dyspnea, coughing, choking,
and dysphagia. This form is more common in
young cats, 1-2 years old. Radiographically,
a widened anterior mediastinum may be pres-
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ent; but visualization of thoracic structures
may be obscured by pleural effusion. The
trachea is usually deviated dorsally. Diagnosis
is made by thoracentesis with microscopic
observation of large numbers of immature or
abnormal lymphocytes in the pleural fluid.
In alimentary lymphosarcoma the major le-
sions are in the GI tract and mesenteric lymph
nodes with infiltration of liver and spleen
common. Single or nlultiple mesenteric
lymph nodes are frequently enlarged, and the
stomach or intestines may be diffusely thick-
ened or contain a single segmental mass. The
terminal ileum is a frequent primary site.
Bone marrow infiltration may also be seen.
Clinical signs usually are those of a digestive
disturbance, Le., diarrhea, constipation, and
anorexia. Palpation of firm, painless enlarge-
ments in the midabdomen is a major finding.
Multicentric lymphosarcoma is a dissemin-
ated form seen in a small number of cats and
is characterized by bilateral enlargement of
superficial lymph nodes and variable infiltra-
tion of organs such as liver, spleen, kidneys,
lungs, myocardium, GI tract, eye, skin, spinal
cord, and bone marrow. Splenomegaly,
hepatomegaly, and enlargement of kidneys
are common. Symptoms are variable and
related to the organs involved. Renal infiltra-
tion with neoplastic cells is frequently seen.
The lesions may be unilateral or bilateral and
clinical signs are associated with renal failure.
Uremia is usually present. Nonspecific signs
include fever, anemia, stomatitis, upper
respiratory infections, and weight loss.
Hematologic involvement is seen in about
15% of the cases of lymphosarcoma. In these
cases anemia, leukopenia, and thrombocyto-
penia may develop.
A final classification is that of true
leukemia. Cats with solid tumors of lympho-
sarcoma usually have normal blood counts. In
recent years there has been an increase in in-
cidence of primay leukemia involving blood
and bone marrow without solid tumors.
Clinical signs are vague and include lethargy,
anorexia, weight loss, anemia, and sometimes
fever. Diagnosis is made by blood examina-
tion. Anemia is usually nonregenerative and
total WBC counts are usually normal or
below normal although some cases do occur
with WBC counts greater than 400,000. 3
Neutropenia often is present and predisposes
to infection. Total lymphocyte count may be
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high or low with variable numbers of ab-
normal cells. Platelet numbers are variable.
Persistence of immature lymphocytes in the
blood, especially in anemic cats, warrants
bone marrow examination. Normal cats have
less than 20% normal lymphocytes (most have
less then 10%). A positive diagnosis can be
made if greater than 40% of the nucleated
marrow cells are lymphocytes and the majori-
ty of these are prolymphocytes or blasts.
Cats in the preleukemic state have vague or
occasionally no signs of illness except a mild
anemia (PCV of 25-30) with a few atypical
lymphocytes. No specific treatment is in-
dicated except to treat any coexisting prob-
lem such as infection. These cats should be
closely monitored for leukemia or other dis-
eases. 2
FeLV also causes immunosuppression with
increased susceptibility to various infections
resulting from cell mediated and humoral im-
munodeficiency. Because of this many adult
cats with persistent FeLV infections have
chronic or recurrent disease problems. A high
incidence of FeLV infection has been ob-
served in cats with infectious peritonitis, in-
fectious anemia, toxoplasmosis, stomatitis,
and respiratory disease, evidently because the
virus lowers their resistance. Poor response to
treatment may result in chronic illness.
Glomerulonephritis is suspected to be caused
by formation of FeLV antigen-antibody com-
plexes in renal glomeruli, and the virus may
have a causative role in fetal absorption and
abortion. t ,2
DISCUSSION
In many exposed cats a humoral antibody
response suppresses development of the
disease. Virus-neutralizing antibodies protect
against virus infection, and antibody against
surface antigen or infected cells (feline
oncornavirus-associated cell membrane anti-
gens, or FOCMA) prevent tumor formation.
These antibodies are transferred in colostrum
from immune queens, thus providing tem-
porary protection for their kittens.
The most practical means for diagnosis is
the direct immunofluorescence technique
which detects FeLV antigen on platelets and
leukocytes in blood smears. Recently an in-
hospital ELISA test for FeLV has been made
commercially available to the practitioner.
One report claims it is faster, more accurate,
Vol. 44, Issue No. 1
and less expensive than the FA test but it is
best suited for hospitals in which several
samples per week are tested for FeLV .9
Two serological tests have been developed
for detection of antibody to FeLV or FeLV in-
duced antigen. The FOCMA test detects
serum antibodies to new cell surface antigens
induced by the virus (not the virus itself).
Becuase FOCMA is present on the surface of
FeLV transformed cells, antibodies against
FOCMA are thought to protect infected cats
from tumor development. Antibody to
FOCMA does not react with the virus and so
does not interfere with the viremia. In in-
fected cats, high FOCMA titers have been
shown to prevent lymphosarcoma develop-
ment.
The virus neutralizing antibody test
measures antibody to the virus envelope an-
tigens. It is still only a research tool; if the test
becomes commercially available it will be in-
valuable to the practitioner. By utilizing tests
that detect both virus and virus-neutralizing
antibodies, it will be possible to determine
whether a cat is susceptible, has been previ-
0usly infected, or is viremic. Knowledge of a
cat's disease status will be valuable to catteries
and multiple cat households as testing can be
directed toward susceptible animals and not
the entire population. Previously infected but
recovered cats can then be kept in a breeding
situation. 1,2
Even with treatment, lymphosarcoma
should be considered an incurable disease at
this time. Although an occasional cat will be
cured, most will eventually die of the disease.
Therefore, the goal of therapy is remission.
But before an owner decides to treat a FeLV-
infected cat, he should have an understand-
ing of the disease, the potential danger to
other cats, prognosis, potential side effects of
the treatment, frequency of clinic visits, and
cost. The patient should be treated on an out-
patient basis, and the veterinarian must make
certain that emergency care is available since
serious problems may abruptly arise during
the course of treatment.
If treatment of the disease is desired,
further patient evaluation is necessary to
determine the extent of the disease and
whether secondary problems are present.
Primary problems referable to organ dysfunc-
tion may include renal failure, dyspnea,
vomiting, or posterior paralysis, and the clini-
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cian must try to judge whether these problems
would be reversible with chemotherapy.
Myelosuppressive drugs used in chemother-
apy predispose the cat to infection which
severely limits drug treatment. If anemia is
present,. myelosuppressive drugs should be
lJsed only if supportive measures including
blood transfusions are available. They should
also not be used if leukopenia and thrombocy-
topenia is present, as routine replacement of
WBC's and platelets is not practical in cats.
Low neutrophil counts predispose to infection
and to thrombocytopenia which, although oc-
curring less frequently, is a grave prognostic
sign. Although fever may be directly
associated with lymphosarcoma, infection
may be present, so urine and blood cultures
should be run. Any infection should be
treated aggressively with antibiotics and in
the same manner it would be treated in a non-
FeLV infected cat. In summary, the ideal cat
to treat is afebrile with normal blood para-
meters, no coexisting infection, and normal
liver and kidney function. 2
The currently employed methods of the~­
apy include surgery, irradiation, and
chemotherapy. The rare solitary lymphosar-
coma may be managed by localized forms of
therapy such as surgical excision (followed by
chemotherapy) or irradiation. Lymphoid ne-
oplasms are very radiosensitive; but because
they are generalized, radiation treatment is
precluded.
Chemotherapy is divided into three stages:
induction of remission, maintenance, and
relapse or recurrence therapy. All currently
used methods differ somewhat in each of
these stages, modifications will be made as
knowledge of existinJ{ druJ{s improves and as
new drugs become ~vaila-ble. Prednisolone,
cyclophosphamide, cytosine arabinoside, and
vincristine are drugs widely used to reduce
tumor mass and establish clinical remission.
Combination therapy with these drugs en-
hances their efficacy, as each drug has a dif-
ferent mechanism of action and different tox-
icity. Therefore, the effect on the malignant
cell is additive while the toxicity is not. Using
chemotherapeutic drugs in combination, re-
sults in the percentage an4 length of remis-
sion to be greater than if they were used
alone.
Treatment must be aggressive, risking some
side effects to obtain longer remission. Remis-
sion is acheived when clinical signs of disease
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have disappeared and laboratory determina-
tions fail to reveal the presence of tumor cells,
which is usually 2-6 weeks.
Patient monitoring and supporitve care are
important. Bactericidal antibiotics are given
if fever develops, and anticancer drugs are
temporarily discontinued if leukopenia or
thrombocytopenia develops. Cytotoxic drugs
are not indicated if leukopenia or anemia is
present. In such cases prednisone and L-
asparaginase are used initially until the mar-
row regenerates sufficiently to allow the use of
cytotoxic drugs. If induction of remission can-
not be achieved with the drugs listed earlier,
other drugs may be used. They include vin-
blastine, adriamycin, chlorambucil, L-
asparaginase, and bleomycin. Following in-
duction of remission, maintenance chemo-
therapy is given using drugs and doses similar
to induction remission, but at longer inter-
vals.
With time, tumor cells often become resist-
ant to the drug used in induction and
maintenance therapy. Following relapse a
second remission is difficult to attain; if a
remission does occur, it is usually of short
duration. This second remission can some-
times be achieved by using the inducing drugs
at high initial dosages or by using the alter-
native cytotoxic drugs. 1
Data from Angell Memorial Animal Hos-
pital in Boston indicates that the length of
remission, using their drug schedules, varies
greatly, with a median of about four months.
It is not unusual for cats to do well from six to
ten months, and rarely a cat will be cured.
However, some cats, particularly those with
leukemia, anemia, or leukopenia, may not
respond. Treatment may be stopped after
continuous complete remission of one year.
Causes of death include relapses, anemia
refractory to transfusion therapy, and infec-
tion caused by myelosuppression due to
chemotherapy or direct immunosuppression
of FeLV.2
As far as prevention is concerned, there are
no vaccines commercially available, though
research on live and inactivated FeLV vac-
cines is being done!L12 If FeLV is a problem
in a cattery, the best method to eliminate in-
fection is to identify carriers and eradicate
them. The remaining virus-negative cats
should be retested at three month intervals,
and after two negative tests the cattery may be
free of infection. If a positive cat is going to
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become negative it will most likely do so
within three months, and it may be possible to
isolate FeLV. Concurrently, with elimination
of positive cats the premises should be rid of
the virus. The virus is destroyed by 70%
alcohol and most detergents and disinfec-
tants.
In a multiple cat household, the diagnosis
of one FeLV positive cat means the other cats
in the house are already exposed. Therefore,
elimination of this cat for the protection of
others is useless unless other FeLV positive
cats are also eliminated. Any FeLV positive
cat should be kept indoors to protect other
cats and to protect the positive cat from ex-
posure to other infections to which he is
susceptible. 13
There has been considerable controversy
about the potential health hazard of FeLV to
man. The FeLV will grow in human cells in
tissue culture; and although serological
studies have shown antibodies to various
FeLV associated antigens in human serum,
they have indicated that there is no positive
association between FeLV and leukemia in
man.
There is no increased evidence of leukemia
in veterinarians or in families who have own-
ed cats with lymphosarcoma, and no in-
stances of human leukemia have ever been
traced to cats. Therefore, the decision to
euthanize an animal on the basis of danger to
man is unfounded and instead should be
based on the type and severity of the disease,
the owner's feeling toward the animal, and
the animal's potential for infecting other cats.
BIBLIOGRAPHY
1. Pedersen, NC: Madewell, BR: Feline Leukemia
Virus Disease Complex, In: Current Veterinary
Therapy VII, Kirk RW, WB Saunders Company,
Philadelphia, PA. 1980, pp 404-410.
2. Cotter, Susan M: Feline Leukemia Virus-Associ-
ated Diseases In: Current Veterinary Therapy VI,
Kirk RW, WB Saunders Company, Philadelphia,
PA. 1977, pp 465-472.
3. RL Ott: Feline Leukemia. In: Felz'ne medicine and
Surgery, 2nd ed, Catcart:EJ: American Veterinary
Publications, Inc, Santa Barbara, CA. 1975, pp
54-62.
4. Catcart, EJ, Smithcors, JF: Neoplastic Diseases. In:
Progress in Fel'ine Practice, Vol. II. American
Veterinary Publications, Inc, Wheaton, IL. pp
163-179.
5. Chapman, WL, Jr: Diseases of the Lymph Nodes
and Spleen-Feline Lymphosarcoma. In: Textbook
of Veterinary Internal Medicine II, Ettinger SJ, WB
Saunders Company, Philadelphia, PA. 1975, pp
1668-1670.
6. Moulton, JE; Dungworth DL: Tumors of the
Lymphoid and Hemopoietic Tissues - Lympho-
sarcoma of the Cat. In: Tumors in Domestic
Anz'mals, 2nd ed. University of California Press,
Berkeley, CA. 1978, pp. 160-164.
7. Bostock, DE; Owen, LN: The Lymphoid and Vascu-
lar Tz'ssue z'n Neoplasia in the Cat, Dog, and Horse.
Year Book Medical Publishers, Inc, Chicago, IL.
1975, pp 126-132.
8. Second Annual San Diego Veterinary Conference,
VMA Veterinary Oncology, Feb. 21-23, 1979, pp
119-120.
9. Sodikoff C: In-hospital FeLV Testing, In: Modern
Veterinary Practz"ce, 60:11, pp 946-947,1979.
10. Francis DP; Essex, M; Gazzagian D: FeLV: Survival
Under Home and Laboratory Conditions. In: J.
CUn. Micro. 9: pp 154-156, 1979.
11. Pedersen NC; Theilen, GH; Werner LL: Safety and
Efficacy of Live and Killed Feline Leukemia Virus
Vaccine. In Am. J. Vet. Res. 40: pp 1120-1126,
1979.
12. Olsen RG: Immunoprevention of Feline Leukemia.
Fed. Proc. 9:4, pp 16-20, 1979.
13. Weyer K; Daams JH: The Control of Lymphosar-
coma/Leukemia and Feline Leukemia Virus. In: J.
SmallAnim. Pract. 19: pp 631-637,1978.
Vol. 44, Issue No. 1 11
